Also published as: Sung-Hou Kim, H S Kim, Suhyung Kim, Jong-Ho Kim, Mi Ok Kim, Jong Heon Kim, S Y Kim, Chul-Hong Kim, Do Hyung Kim, Sydney Y Kim, Sung Young Kim, So Young Kim, Yeonsoo Kim, Chongtae Kim, Jiha Kim, Myung-Sunny Kim, Hyeong-Rok Kim, Young-Youn Kim, Hye Yun Kim, Miri Kim, Dong Il Kim, Hyeon-Ah Kim, Arie Kim, Esther Kim, Ok-Hwa Kim, Sun-Hee Kim, Juyong B Kim, Joong-Seok Kim, Jong Woo Kim, Saerom Kim, Wondong Kim, Seong-Hyun Kim, Misung Kim, Min Wook Kim, Dong-Ik Kim, Minsuk Kim, Hyung-Jun Kim, Ohn Soon Kim, Sung Han Kim, Jae Hyun Kim, Sewoon Kim, Sung Tae Kim, Richard Kim, Albert H Kim, Ju Deok Kim, Jin Seok Kim, Chong Ae Kim, Hyun-Ji Kim, Yong Kyung Kim, Eunju Kim, Yun Hye Kim, Sun-Hong Kim, Soyeong Kim, Sowon Kim, Young Sik Kim, Jisun Kim, Mi-Hyun Kim, Haein Kim, Byung-Gyu Kim, Jeonghan Kim, JongKyong Kim, Jin Young Kim, So Ree Kim, Hee Jin Kim, Minjae Kim, Hyun Kim, Kyoung Oh Kim, Jiyea Kim, Jun Hoe Kim, Joon Kim, Sunghwan Kim, Bo-Rahm Kim, Namkyoung Kim, Hee Jeong Kim, Aram Kim, Youn-Jung Kim, Joung Sug Kim, Kangjoon Kim, Hail Kim, Younghoon Kim, Eui Jin Kim, Cheol-Su Kim, Jae Geun Kim, Min Kyeong Kim, Ngoc Thanh Kim, Seong-Seop Kim, Ji-Man Kim, Ju-Kon Kim, Hyeong-Taek Kim, Soo Wan Kim, Woong-Ki Kim, Ju-Wan Kim, Sunggun Kim, Kevin K Kim, Sun Woong Kim, Soeun Kim, Jin Kyong Kim, Hoguen Kim, Sungup Kim, Hyungkuen Kim, Ji Hye Kim, Myoung Hee Kim, Min Ju Kim, Jeong Su Kim, Gwang Sik Kim, Anthony S Kim, Ok Jin Kim, Jeongseop Kim, Bo-Eun Kim, Suk-Kyung Kim, Deok-Ho Kim, Woo-Shik Kim, Sang Soo Kim, Hae Won Kim, Mina K Kim, Kiyoung Kim, Paul H Kim, Taeil Kim, Eun-Kyung Kim, Joonyoung R Kim, Da-Sol Kim, Yeaseul Kim, In Ja Kim, Beomsu Kim, Byungwook Kim, Kyung-Hee Kim, Hyeyoon Kim, Sun Yeou Kim, Hyojin Kim, Jongmyung Kim, Yangseok Kim, Jong Ho Kim, Chunki Kim, Seokjoong Kim, Helen Kim, Sungyeon Kim, Mi Ra Kim, Dae-Eun Kim, Young-Dae Kim, Young Mi Kim, Na-Kuang Kim, Yoon Sook Kim, Jayoun Kim, Byoung Jae Kim, Jung Dae Kim, Joseph Han Sol Kim, Daham Kim, Mijung Kim, Yu Kyeong Kim, Yong-Lim Kim, E-S Kim, Jin-Chul Kim, Chan Wook Kim, Hyeong-Jin Kim, Boo-Young Kim, Sang Hyuk Kim, Sung-Mi Kim, Dongwoo Kim, Seul-Ki Kim, Hye Jin Kim, Gibae Kim, Soo Young Kim, Sang Ryong Kim, Sukjun Kim, Dong Joon Kim, Hyo Jung Kim, Yeseul Kim, Jieun Kim, Jongchan Kim, Joseph C Kim, Yong Sik Kim, Nam-Eun Kim, Jun Pyo Kim, Sang-Tae Kim, Brandon J Kim, Hong Sug Kim, Youngjoo Kim, Sun-Gyun Kim, Min-Gon Kim, Young-Woo Kim, Myungshin Kim, Tae Hoen Kim, Soon Hee Kim, Won Kim, Chanhee Kim, Jung Oh Kim, Jun-Sik Kim, Ji Eun Kim, Hyun-Kyong Kim, Jeffrey Kim, Yeonhwa Kim, Jung-In Kim, Chan-Wha Kim, B-Y Kim, B T Kim, Dahee Kim, Taek-Yeong Kim, Yeon Ju Kim, Duck-Hee Kim, Hyunjoon Kim, Young-Saeng Kim, Seohyeon Kim, Soon Sun Kim, Hyeon Jeong Kim, Jae Bum Kim, Yeul Hong Kim, Hyemin Kim, Shin Kim, Juhyun Kim, Chang-Gu Kim, Y S Kim, Dan Say Kim, Ji-Dam Kim, Gwangil Kim, Alison J Kim, Paul T Kim, Kyoung Hoon Kim, Hwa-Jung Kim, Ye-Ri Kim, Youngeun Kim, Cheol-Hee Kim, Hee-Jin Kim, Jason Kim, Youngsin Kim, NamHee Kim, Hyuk Soon Kim, Byung-Chul Kim, Cecilia Kim, S Kim, Tae-Gyu Kim, Kwan-Suk Kim, Seung-Ki Kim, Jee Ah Kim, Moon Suk Kim, Young Ju Kim, Kyoungtae Kim, Yunwoo Kim, J Y Kim, Lia Kim, Soo-Hyun Kim, Byung Jin Kim, You-Sun Kim, Seong Jun Kim, Youngsoo Kim, Yunkyung Kim, Mi Jeong Kim, Myoung Sook Kim, Meelim Kim, Kye-Seong Kim, Chu-Young Kim, Minseon Kim, Minsu Kim, Hye-Jin Kim, Il-Man Kim, Seong-Tae Kim, Dong Ha Kim, Soo Yoon Kim, Donghyeon Kim, Sunoh Kim, Yu-Jin Kim, Yul-Ho Kim, Stuart K Kim, Eric Kim, Soo Hyun Kim, Jae-Young Kim, Jin Hee Kim, Tae Min Kim, Il-Chan Kim, Mi-Na Kim, Yeji Kim, Yo-Han Kim, Yeong-Sang Kim, Eunmi Kim, Taewan Kim, Kyong-Tai Kim, Dae-Kyeong Kim, Yun Seok Kim, Kyung Hee Kim, M Kim, June Hee Kim, Hyun Eun Kim, Eunkyeong Kim, Tae Hyun Kim, Soee Kim, Young-Im Kim, So-Hee Kim, Hyeong Hoe Kim, Hee Young Kim, Leo A Kim, Eungseok Kim, Sungyun Kim, Young S Kim, Min Bum Kim, Min Seo Kim, Tae-You Kim, Jong-Yeon Kim, Tae Hoon Kim, Sungrae Kim, Eun-Jin Kim, Heejin Kim, Tae Jin Kim, Seong-Jin Kim, Young-Chul Kim, Jinkyeong Kim, SooHyeon Kim, Ju Young Kim, Kwangwoo Kim, Un-Kyung Kim, Dong-Hee Kim, Sang Wun Kim, Jin Woo Kim, Gu-Hwan Kim, Young-Mi Kim, Dae-Kyum Kim, Won J Kim, Seung Won Kim, Tae-Min Kim, Seon-Kyu Kim, Hana Kim, Hye Ran Kim, Ji-Yul Kim, Moo-Yeon Kim, Do Yeon Kim, Jun Seok Kim, Su-Jin Kim, Yuli Kim, Jung Ho Kim, Edwin H Kim, Jewoo Kim, A Ram Kim, Grace Kim, Jongho Kim, Hyung Hoi Kim, Soung Jung Kim, Song-Rae Kim, Jinsup Kim, Dong-Kyu Kim, Su-Hyeong Kim, Hye-Ran Kim, Kee-Tae Kim, Nam-Ho Kim, Yoongeum Kim, Jeong-Han Kim, Jin Gyeom Kim, Jinsoo Kim, Mi Young Kim, Hyun-Sic Kim, Steve Kim, Kyung-Sup Kim, Taeyoung Kim, Hyeonwoo Kim, Dong Gwang Kim, Jong-Youn Kim, Hwi Seung Kim, Doo Yeon Kim, Hye Ree Kim, Hyeong-Geug Kim, Jong-Il Kim, Soo Whan Kim, Kwang-Eun Kim, Jong-Won Kim, Eung-Gook Kim, Jaehoon Kim, Yu Mi Kim, J H Kim, Hyoung Kyu Kim, Hark Kyun Kim, Suk Jae Kim, Sung-Hee Kim, Jonggeol J Kim, Sang Eun Kim, Na-Young Kim, Minji Kim, Jeong Kyu Kim, Jongkyu Kim, Jae-Yoon Kim, Hyunjin Kim, Eun Ji Kim, Youngmi Kim, William Kim, Helen B Kim, Jiho Kim, Dae In Kim, Dennis Y Kim, Sunghun Kim, Nari Kim, Doyeon Kim, Sang-Min Kim, Dong-Yi Kim, Myeong-Kyu Kim, Youngsook Kim, Ji-Yun Kim, Sung Woo Kim, Ha-Jung Kim, Yongmin Kim, Angela H Kim, Han Young Kim, Hye-Jung Kim, Hyun-Soo Kim, Hyunju Kim, Jin Man Kim, Hyung-Suk Kim, Young Nam Kim, Hang-Rai Kim, Hyoun-Ah Kim, Hye Young Kim, Sung-Wan Kim, Sung Yeol Kim, Jong-Oh Kim, Y-D Kim, Jong-Hyun Kim, Myung-Sun Kim, Jenny H Kim, Youngchang Kim, Mi Kyung Kim, Eun Young Kim, Okhwa Kim, Jinhee Kim, Y A Kim, Won Kyung Kim, Hyung-Gu Kim, Dongjoon Kim, Woo Sik Kim, Myung Jin Kim, In Suk Kim, Hannah Kim, Ick Young Kim, Hyunsoo Kim, Sung Eun Kim, Yekaterina Kim, Sungjoo Kim, Seonhee Kim, Y-M Kim, Sun Hee Kim, Juyoung Kim, Jung Sun Kim, Ji Young Kim, Hong-Hee Kim, Hye-Sung Kim, Sung-Eun Kim, Wun-Jae Kim, Ji Hyun Kim, Kyung Mee Kim, Hee Nam Kim, Sunghak Kim, Dong-Hoon Kim, Vladimir Kim, Yong-Wan Kim, Seul Young Kim, Myoung Ok Kim, Jong-Seok Kim, H Kim, Minsik Kim, Sang-Young Kim, Donghee Kim, June-Bum Kim, Dong Hyun Kim, Sang Jin Kim, Jihoon Kim, Won Ho Kim, Byeong-Won Kim, Jaegil Kim, Hyung-Goo Kim, Tae Wan Kim, Seonggon Kim, J Julie Kim, Jiwon Kim, Eun-Joo Kim, Seongho Kim, Hyun Soo Kim, Dong Wook Kim, Tae-Hyoung Kim, Anna Kim, Gahyun Kim, Jun-Hyung Kim, Don-Kyu Kim, Jong Hwan Kim, Kyung An Kim, Jun Suk Kim, Borahm Kim, Caroline Kim, Andrea J Kim, Jung-Lye Kim, Yong-Hoon Kim, Dongkyun Kim, Sung Kyun Kim, Jisup Kim, Yong Kyun Kim, Yerin Kim, Young-Eun Kim, Seung Woo Kim, Jun W Kim, Angela Kim, Eunae Kim, Tae-Eun Kim, Won Tae Kim, Kyung-Sub Kim, Ji Won Kim, Sang Geon Kim, Kang Ho Kim, Young-Cho Kim, Chul Hwan Kim, Bo Young Kim, Yong Sig Kim, Hong-Kyu Kim, Go Woon Kim, Minsoon Kim, Peter K Kim, Taeeun Kim, Eunhyun Kim, Min-Sik Kim, Paul Kim, Jeongseon Kim, Hyejin Kim, Chang-Yub Kim, Kyunggon Kim, Sinai Kim, Tae-Mi Kim, Oc-Hee Kim, Da-Hyun Kim, Jong Geun Kim, Woo Kyung Kim, Jae-Yong Kim, Jiyeon Kim, Jaeuk U Kim, Kye Hyun Kim, Dae-Jin Kim, Chong Kook Kim, Minkyung Kim, Jun Chul Kim, Cecilia E Kim, Jae Seon Kim, Yeon-Jeong Kim, Ha-Neui Kim, Kwan Hyun Kim, Dae Keun Kim, You Sun Kim, Heung-Joong Kim, Jongwan Kim, Angela S Kim, Young Hun Kim, Nam Hee Kim, Jong Yeol Kim, Ji-Young Kim, So-Woon Kim, Dayoung Kim, Sangwoo Kim, Ji-Hoon Kim, Ki Tae Kim, Young-Bum Kim, Eric Eunshik Kim, Hyojung Kim, Yeeun Kim, Jeewoo Kim, Sungmin Kim, Hyun Sil Kim, Young Hee Kim, Woonhee Kim, Minjeong Kim, Sae Hun Kim, Sohee Kim, Kyunga Kim, Donghyun Kim, Sung-Kyu Kim, Hanah Kim, Do-Kyun Kim, Jong-Joo Kim, Sangsoo Kim, Yong-Woon Kim, Jonggeol Jeffrey Kim, Geun-Young Kim, Jae-Jun Kim, Min Soo Kim, K-K Kim, Jung-Taek Kim, Ju Han Kim, Jeeyoung Kim, Hyung Yoon Kim, Min-Sun Kim, Youngchul Kim, Minhee Kim, Byung-Taek Kim, Sung-Bae Kim, Kwang Pyo Kim, Suk-Jeong Kim, Min-A Kim, Ngoc-Thanh Kim, Jae T Kim, Chan-Duck Kim, Dong-Seok Kim, Hyeon Ho Kim, Soo-Youl Kim, Min-Seon Kim, Young Tae Kim, Hyoun Ju Kim, Shi-Mun Kim, Kwang-Pyo Kim, Hee Jong Kim, JungMin Kim, Minah Kim, Taehyoun Kim, Kwonseop Kim, Yonghwan Kim, Kyong Min Kim, Won Dong Kim, Su-Jeong Kim, Jae-Jung Kim, Eunha Kim, Howard H Kim, Min-Hyun Kim, Kyeongjin Kim, Min Kim, Sung Won Kim, Min-Seo Kim, Se-Wha Kim, Myeoung Su Kim, Minjoo Kim, Sujung Kim, Eonmi Kim, In-Hoo Kim, Woo-Kyun Kim, Nan Young Kim, Myeong Ok Kim, Yongjae Kim, Wootae Kim, Jong-Kyu Kim, In Kyoung Kim, Leen Kim, Doo Yeong Kim, Do-Hyung Kim, Dong-il Kim, Jeri Kim, Dong-Hyeok Kim, Seol-A Kim, Soriul Kim, Kil-Nam Kim, Joonseok Kim, Soo-Rim Kim, So Yeon Kim, Kwangho Kim, Yun-Jin Kim, Yeonjung Kim, Seok Won Kim, Bo Ri Kim, Su Jin Kim, TaeHyung Kim, Kyung Woo Kim, Woo Jin Kim, Yeon-Jung Kim, Misun Kim, Serim Kim, Jeong Hee Kim, Youn Shic Kim, Junesun Kim, Dong-Eun Kim, Young Ree Kim, So-Yeon Kim, Choel Kim, Jae Hun Kim, C H Kim, Sung-Hoon Kim, Namphil Kim, Kyung-Chang Kim, Jin-Soo Kim, Jimi Kim, You-Jin Kim, Goun Kim, Goo-Young Kim, Chan-Hee Kim, Jong Han Kim, Bongjun Kim, Sun-Joong Kim, Sun Hye Kim, Seulhee Kim, Joonyoung Kim, Gunhee Kim, Joungmok Kim, Young Ho Kim, Seung-Whan Kim, Sang-Woo Kim, Seongmi Kim, Kyung Sup Kim, Young Jin Kim, Scott Y H Kim, Chang Seong Kim, Ryung S Kim, Daegyeom Kim, Da Sol Kim, Ellen Kim, Kellan Kim, Young Rae Kim, Hee-Sun Kim, Seung Jun Kim, Han Gyung Kim, Jae Hoon Kim, Kyungjin Kim, Youn-Kyung Kim, Jung-Ha Kim, Sunghoon Kim, Jung-Hyun Kim, Jaeyeon Kim, Hyung-Mi Kim, Young Eun Kim, Hye-Young H Kim, Ho Shik Kim, Ho-Sook Kim, Hyun Ju Kim, Hwijin Kim, Gyeonghun Kim, Kyungtae Kim, Baek Kim, Soon-Hee Kim, David E Kim, Ki Kwon Kim, Joong Sun Kim, Yongae Kim, Jaemi Kim, Hyun-ju Kim, Tai Kyoung Kim, Hoon Seok Kim, Yunjung Kim, Keun You Kim, Se Hyun Kim, Min Cheol Kim, Gye Lim Kim, Hyeseon Kim, Jin Cheon Kim, Hyung-Ryong Kim, Carla F Kim, Hyunki Kim, Dakyung Kim, Yong-Sik Kim, Jong Won Kim, Hoon Kim, Seung-Jin Kim, Myeong Ji Kim, Joonki Kim, NamDoo Kim, Jinho Kim, Hyo Jong Kim, Young-Woong Kim, Un Gi Kim, Tae-Hyun Kim, Hyung-Sik Kim, Ah-Ram Kim, Kee-Pyo Kim, Oh Yoen Kim, Juyeong Kim, Deok Ryong Kim, Jun Hee Kim, Hyunyoung Kim, Jung Ki Kim, Yongkang Kim, Chae-Hyun Kim, Brian S Kim, Minchul Kim, Leo Kim, Eun Ho Kim, Haeryoung Kim, Seong Kim, Jessica Kim, Kahye Kim, Jae-Ryong Kim, Jin Won Kim, Hyun Sook Kim, Kyeongmi Kim, Rosalind Kim, Heegoo Kim, Sujin Kim, In Joo Kim, E Kim, Sung-Jo Kim, Sang Chan Kim, Kyuho Kim, Nam-Hyung Kim, Sin Gon Kim, Sunkyu Kim, Seohyun Kim, Beom-Jun Kim, Boram Kim, Kyeong Jin Kim, Wanil Kim, Gi Beom Kim, Hei Sung Kim, Jason K Kim, Woojin Scott Kim, Hyung-Seok Kim, Won Jeoung Kim, Jungwoo Kim, Dae Hyun Kim, Yejin Kim, Jina Kim, Kyu-Kwang Kim, Yong-Soo Kim, Yong-Ou Kim, M J Kim, Ji-Won Kim, Yoonjung Kim, Chul Hoon Kim, Hyun-Jung Kim, Jae Hyoung Kim, Eui-Soon Kim, Hyun Joon Kim, Minkyeong Kim, M V Kim, Hyun-Jin Kim, Ok-Kyung Kim, Yumi Kim, Kyungsook Kim, Kyungwon Kim, Sunyoung Kim, Jin Kim, Suji Kim, Ok-Hyeon Kim, Maya Kim, Mijeong Kim, Jung-Woong Kim, Seoyeon Kim, Hyunbae Kim, Esl Kim, Kyeong-Min Kim, Sang-Hoon Kim, Hyun Gi Kim, Jooho Kim, Su Kang Kim, Ju-Ryoung Kim, Myung-Jin Kim, Eun-Jung Kim, Sangchul Kim, Bomi Kim, Kyung Han Kim, Seoyoung Kim, Ji-Eun Kim, Yoojin Kim, Joori Kim, Min Jung Kim, Minju Kim, Jeeho Kim, Tae-Woon Kim, Jihye Kim, Jae Gon Kim, Hyeong Su Kim, Choon-Song Kim, Kye Hun Kim, Mi-Young Kim, Choon Ok Kim, Hyesung Kim, Na Yeon Kim, Seong-Ik Kim, Yeon-Ki Kim, Jisu Kim, Jaeyoon Kim, Dong-Hyun Kim, Myungsuk Kim, Kook Hwan Kim, Eui Hyun Kim, Won-Tae Kim, Sung Soo Kim, Sung Hyun Kim, Eun Kim, Hyung Min Kim, Sol Kim, Jihyun Kim, Hyunwoo Kim, Kwang Dong Kim, Min Joo Kim, Suhyun Kim, Elizabeth H Kim, Sang-Gun Kim, Han-Kyul Kim, Dong-Wook Kim, Young Sam Kim, Yong Deuk Kim, Jong-Seo Kim, Young-Ho Kim, Yoo Ri Kim, Hye-Yeon Kim, Eiru Kim, Ji Yeon Kim, Ki Hyun Kim, Tae Hun Kim, Ae-Jung Kim, Yun Joong Kim, Eosu Kim, Ki Woong Kim, Cheorl-Ho Kim, TaeYeong Kim, Yeon-Hee Kim, Jae Suk Kim, Richard B Kim, Jungsu Kim, Young-Jin Kim, Deokhoon Kim, Eung Yeop Kim, Misu Kim, Seung Chul Kim, Mi-Yeon Kim, K-S Kim, Hyo-Soo Kim, Daeseung Kim, Won Kon Kim, Sangmi Kim, Jong Deog Kim, Yun Gi Kim, Seon-Young Kim, Il-Sup Kim, Ji Hun Kim, Byung Guk Kim, Susy Kim, Youngwoo Kim, Mi-Sung Kim, Min-Young Kim, Jae-Min Kim, Young Woo Kim, Yong Sung Kim, Young-Won Kim, Taehyeung Kim, Meesun Kim, Sook Young Kim, Jaewon Kim, Jung H Kim, In Su Kim, Eun Hee Kim, Yong Kwan Kim, Haelee Kim, Daesik Kim, Heebal Kim, Seungsoo Kim, Bong-Jo Kim, Woo-Jin Kim, Seon Hwa Kim, Luke Y Kim, Jae-Ick Kim, Hwajung Kim, Jisook Kim, Jeffrey J Kim, Kyung Do Kim, Gukhan Kim, Jungeun Kim, Youbin Kim, Jeong-Min Kim, Hyungjun Kim, Young-Hoon Kim, Seokhwi Kim, Jong-Ki Kim, Byron Kim, Taek-Kyun Kim, D-W Kim, Bo-Ra Kim, Dokyoon Kim, Su-Yeon Kim, Min Chul Kim, Jung Hee Kim, Wook Kim, Jun-Mo Kim, Miso Kim, Seong-Min Kim, Jang Heub Kim, Seon Hee Kim, Hong-Gi Kim, Hyun-Young Kim, Young Hwa Kim, Hyeyoung Kim, Hyunwook Kim, Hyung Bum Kim, Dae-Soo Kim, Hee Su Kim, Gitae Kim, Hyun-Yi Kim, Sejoong Kim, Young-Joo Kim, Reuben H Kim, Hong-Kook Kim, Hyungsoo Kim, Soo Jung Kim, Sungryong Kim, Hyunmi Kim, June Soo Kim, Gyudong Kim, Rokki Kim, Yong Sook Kim, Young-Il Kim, Jinsu Kim, Woo-Yang Kim, Eunjoon Kim, Taejung Kim, Woo Kim, Jang-Hee Kim, Won Seok Kim, Jung Soo Kim, Kyoung Hwan Kim, Sung Mok Kim, Seung Tea Kim, Tae Il Kim, Daeeun Kim, Hyelim Kim, Beomsoo Kim, Ji-Woon Kim
Tumor recurrence by obtaining chemoresistance is a major obstacle to treating ovarian cancer. By TargetScan database and a luciferase reporter assay, we identified miR-150 directly targets
The objective of this study is to find single nucleotide polymorphisms (SNPs) associated with a risk of Type 2 diabetes (T2D) in Korean adults and to investigate the longitudinal association between t Show more
The objective of this study is to find single nucleotide polymorphisms (SNPs) associated with a risk of Type 2 diabetes (T2D) in Korean adults and to investigate the longitudinal association between these SNPs and T2D and the interaction effects of iron intake and average hemoglobin level. Data from the KoGES_Ansan and Ansung Study were used. Gene-iron interaction analysis was conducted using a two-step approach. To select candidate SNPs associated with T2D, a total of 7,935 adults at baseline were included in genome-wide association analysis (step one). After excluding T2D prevalent cases, prospective analyses were conducted with 7,024 adults aged 40-69 (step two). The association of selected SNPs and iron status with T2D and their interaction were determined using a Cox proportional hazard model. A total of 3 SNPs [rs9465871 (CDKAL1), rs10761745 (JMJD1C), and rs163177 (KCNQ1)] were selected as candidate SNPs related to T2D. Among them, rs10761745 (JMJD1C) and rs163177 (KCNQ1) were prospectively associated with T2D. High iron intake was also prospectively associated with the risk of T2D after adjusting for covariates. Average hemoglobin level was positively associated with T2D after adjusting for covariates in women. We also found significant interaction effects between rs10761745 (JMJD1C) and average hemoglobin levels on the risk of T2D among women with normal inflammation and without anemia at baseline. In conclusion, KCNQ1 and JMJD1C may prospectively contribute to the risk of T2D incidence among adults over the age of 40 and JMJD1C, but CDKAL1 may not, and iron status may interactively contribute to T2D incidence in women. Show less
Microtubule-actin crosslinking factor 1 (MACF1), also known as actin crosslinking factor 7 (ACF7), is essential for proper modulation of actin and microtubule cytoskeletal networks. Most MACF1 isoform Show more
Microtubule-actin crosslinking factor 1 (MACF1), also known as actin crosslinking factor 7 (ACF7), is essential for proper modulation of actin and microtubule cytoskeletal networks. Most MACF1 isoforms are expressed broadly in the body, but some are exclusively found in the nervous system. Consequentially, MACF1 is integrally involved in multiple neural processes during development and in adulthood, including neurite outgrowth and neuronal migration. Furthermore, MACF1 participates in several signaling pathways, including the Wnt/β-catenin and GSK-3 signaling pathways, which regulate key cellular processes, such as proliferation and cell migration. Genetic mutation or dysregulation of the MACF1 gene has been associated with neurodevelopmental and neurodegenerative diseases, specifically schizophrenia and Parkinson's disease. MACF1 may also play a part in neuromuscular disorders and have a neuroprotective role in the optic nerve. In this review, the authors seek to synthesize recent findings relating to the roles of MACF1 within the nervous system and explore potential novel functions of MACF1 not yet examined. Show less
GABAergic interneurons develop in the ganglionic eminence in the ventral telencephalon and tangentially migrate into the cortical plate during development. However, key molecules controlling interneur Show more
GABAergic interneurons develop in the ganglionic eminence in the ventral telencephalon and tangentially migrate into the cortical plate during development. However, key molecules controlling interneuron migration remain poorly identified. Here, we show that microtubule-actin cross-linking factor 1 (MACF1) regulates GABAergic interneuron migration and positioning in the developing mouse brain. To investigate the role of MACF1 in developing interneurons, we conditionally deleted the MACF1 gene in mouse interneuron progenitors and their progeny using Dlx5/6-Cre-IRES-EGFP and Nkx2.1-Cre drivers. We found that MACF1 deletion results in a marked reduction and defective positioning of interneurons in the mouse cerebral cortex and hippocampus, suggesting abnormal interneuron migration. Indeed, the speed and mode of interneuron migration were abnormal in the MACF1-mutant brain, compared with controls. Additionally, MACF1-deleted interneurons showed a significant reduction in the length of their leading processes and dendrites in the mouse brain. Finally, loss of MACF1 decreased microtubule stability in cortical interneurons. Our findings suggest that MACF1 plays a critical role in cortical interneuron migration and positioning in the developing mouse brain. Show less
To understand disease mechanisms, a large-scale analysis of human-yeast genetic interactions was performed. Of 1305 human disease genes assayed, 20 genes exhibited strong toxicity in yeast. Human-yeas Show more
To understand disease mechanisms, a large-scale analysis of human-yeast genetic interactions was performed. Of 1305 human disease genes assayed, 20 genes exhibited strong toxicity in yeast. Human-yeast genetic interactions were identified by en masse transformation of the human disease genes into a pool of 4653 homozygous diploid yeast deletion mutants with unique barcode sequences, followed by multiplexed barcode sequencing to identify yeast toxicity modifiers. Subsequent network analyses focusing on amyotrophic lateral sclerosis (ALS)-associated genes, such as optineurin ( Show less
Increased sugar consumption is a risk factor for the metabolic syndrome including obesity, hypertriglyceridemia, insulin resistance, diabetes, and nonalcoholic fatty liver disease (NAFLD). Carbohydrat Show more
Increased sugar consumption is a risk factor for the metabolic syndrome including obesity, hypertriglyceridemia, insulin resistance, diabetes, and nonalcoholic fatty liver disease (NAFLD). Carbohydrate responsive element-binding protein (ChREBP) is a transcription factor that responds to sugar consumption to regulate adaptive metabolic programs. Hepatic ChREBP is particularly responsive to fructose and global ChREBP-KO mice are intolerant to diets containing fructose. It has recently been suggested that ChREBP protects the liver from hepatotoxicity following high-fructose diets (HFrDs). We directly tested this hypothesis using tissue-specific ChREBP deletion. HFrD increased adiposity and impaired glucose homeostasis in control mice, responses that were prevented in liver-specific ChREBP-KO (LiChKO) mice. Moreover, LiChKO mice tolerated chronic HFrD without marked weight loss or hepatotoxicity. In contrast, intestine-specific ChREBP-KO (IChKO) mice rapidly lost weight after transition to HFrD, and this was associated with dilation of the small intestine and cecum, suggestive of malabsorption. These findings were associated with downregulation of the intestinal fructose transporter, Slc2a5, which is essential for fructose tolerance. Altogether, these results establish an essential role for intestinal, but not hepatic, ChREBP in fructose tolerance. Show less
Impaired nutrient sensing and dysregulated glucose homeostasis are common in diabetes. However, how nutrient-sensitive signaling components control glucose homeostasis and β cell survival under diabet Show more
Impaired nutrient sensing and dysregulated glucose homeostasis are common in diabetes. However, how nutrient-sensitive signaling components control glucose homeostasis and β cell survival under diabetic stress is not well understood. Here, we show that mice lacking the core nutrient-sensitive signaling component mammalian target of rapamycin (mTOR) in β cells exhibit reduced β cell mass and smaller islets. mTOR deficiency leads to a severe reduction in β cell survival and increased mitochondrial oxidative stress in chemical-induced diabetes. Mechanistically, we find that mTOR associates with the carbohydrate-response element-binding protein (ChREBP)-Max-like protein complex and inhibits its transcriptional activity, leading to decreased expression of thioredoxin-interacting protein (TXNIP), a potent inducer of β cell death and oxidative stress. Consistent with this, the levels of TXNIP and ChREBP were highly elevated in human diabetic islets and Show less
Regulation of lipogenesis by pathophysiological factors in the liver and skeletal muscle is well understood; however, regulation in the kidney is still unclear. To elucidate nutritional regulation of Show more
Regulation of lipogenesis by pathophysiological factors in the liver and skeletal muscle is well understood; however, regulation in the kidney is still unclear. To elucidate nutritional regulation of lipogenic factors in the kidney, we measured the renal expression of lipogenic transcriptional factors and enzymes during fasting and refeeding in chow-fed and high-fat-fed mice. We also examined the regulatory effect of the liver X receptor (LXR) on the expression of lipogenic factors. The renal gene expression of sterol regulatory element-binding protein (SREBP)-1c and fatty acid synthase (FAS) was reduced by fasting for 48 h and restored by refeeding, whereas the mRNA levels of forkhead box O (FOXO)1/3 were increased by fasting and restored by refeeding. Accordingly, protein levels of SREBP-1, FAS, and phosphorylated FOXO1/3 were reduced by fasting and restored by refeeding. The patterns of lipogenic factors expression in the kidney were similar to those in the liver and skeletal muscle. However, this phasic regulation of renal lipogenic gene expression was blunted in diet-induced obese mice. LXR agonist TO901317 increased the lipogenic gene expression and the protein levels of SREBP-1 precursor and FAS but not nuclear SREBP-1. Moreover, increases in insulin-induced gene mRNA and nuclear carbohydrate-responsive element binding protein (ChREBP) levels were observed in the TO901317-treated mice. These results suggest that the kidney shows flexible suppression and restoration of lipogenic factors following fasting and refeeding in lean mice, but this is blunted in obese mice. LXR is involved in the renal expression of lipogenic enzymes, and ChREBP may mediate the response. Show less
Increased fructose consumption is a contributor to the burgeoning epidemic of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates that the metabolic hormone FGF21 is regulated by fruc Show more
Increased fructose consumption is a contributor to the burgeoning epidemic of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates that the metabolic hormone FGF21 is regulated by fructose consumption in humans and rodents and may play a functional role in this nutritional context. Here, we sought to define the mechanism by which fructose ingestion regulates FGF21 and determine whether FGF21 contributes to an adaptive metabolic response to fructose consumption. We tested the role of the transcription factor carbohydrate responsive-element binding protein (ChREBP) in fructose-mediated regulation of FGF21 using ChREBP knockout mice. Using FGF21 knockout mice, we investigated whether FGF21 has a metabolic function in the context of fructose consumption. Additionally, we tested whether a ChREBP-FGF21 interaction is likely conserved in human subjects. Hepatic expression of In summary, ChREBP and FGF21 constitute a signaling axis likely conserved in humans that mediates an essential adaptive response to fructose ingestion that may participate in the pathogenesis of NAFLD and liver fibrosis. Show less
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR Show more
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations. Show less
Pathogenic variants in genes related to channelopathy and cardiomyopathy are the most common cause of sudden unexplained cardiac death. However, few reports have investigated the frequency and/or spec Show more
Pathogenic variants in genes related to channelopathy and cardiomyopathy are the most common cause of sudden unexplained cardiac death. However, few reports have investigated the frequency and/or spectrum of pathogenic variants in these genes in Korean sudden cardiac arrest survivors. This study aimed to investigate the causative genetic variants of cardiac-associated genes in Korean sudden cardiac arrest survivors. We performed exome sequencing followed by filtering and validation of variants in 100 genes related to channelopathy and cardiomyopathy in 19 Korean patients who survived sudden cardiac arrest. Five of the 19 patients (26.3%) had either a pathogenic variant or a likely pathogenic variant in MYBPC3 (n=1), MYH7 (n=1), RYR2 (n=2), or TNNT2 (n=1). All five variants were missense variants that have been reported previously in patients with channelopathies or cardiomyopathies. Furthermore, an additional 12 patients (63.2%) had more than one variant of uncertain significance. In conclusion, pathogenic or likely pathogenic variants in genes related to channelopathy and cardiomyopathy are not uncommon in Korean sudden cardiac arrest survivors and cardiomyopathy-related genes should be included in the molecular diagnosis of sudden cardiac arrest in Korea. Show less
Macrophages play pivotal roles in the progression and regression of atherosclerosis. Accumulating evidence suggests that macrophage polarization into an anti-inflammatory M2 state is a key characteris Show more
Macrophages play pivotal roles in the progression and regression of atherosclerosis. Accumulating evidence suggests that macrophage polarization into an anti-inflammatory M2 state is a key characteristic of atherosclerotic plaques undergoing regression. However, the molecular mechanisms underlying this potential association of the M2 polarization with atherosclerosis regression remain poorly understood. Further, human genetic factors that facilitate these anti-atherogenic processes remain largely unknown. We report that the transcription factor MafB plays pivotal roles in promoting macrophage M2 polarization. Further, MafB promotes cholesterol efflux from macrophage foam cells by directly up-regulating its key cellular mediators. Notably, MafB expression is significantly up-regulated in response to various metabolic and immunological stimuli that promote macrophage M2 polarization or cholesterol efflux, and thereby MafB mediates their beneficial effects, in both liver x receptor (LXR)-dependent and independent manners. In contrast, MafB is strongly down-regulated upon elevated pro-inflammatory signaling or by pro-inflammatory and pro-atherogenic microRNAs, miR-155 and miR-33. Using an integrative systems biology approach, we also revealed that M2 polarization and cholesterol efflux do not necessarily represent inter-dependent events, but MafB is broadly involved in both the processes. These findings highlight physiological protective roles that MafB may play against atherosclerosis progression. Show less
NRBF2/Atg38 has been identified as the fifth subunit of the macroautophagic/autophagic class III phosphatidylinositol 3-kinase (PtdIns3K) complex, along with ATG14/Barkor, BECN1/Vps30, PIK3R4/p150/Vps Show more
NRBF2/Atg38 has been identified as the fifth subunit of the macroautophagic/autophagic class III phosphatidylinositol 3-kinase (PtdIns3K) complex, along with ATG14/Barkor, BECN1/Vps30, PIK3R4/p150/Vps15 and PIK3C3/Vps34. However, its functional mechanism and regulation are not fully understood. Here, we report that NRBF2 is a fine tuning regulator of PtdIns3K controlled by phosphorylation. Human NRBF2 is phosphorylated by MTORC1 at S113 and S120. Upon nutrient starvation or MTORC1 inhibition, NRBF2 phosphorylation is diminished. Phosphorylated NRBF2 preferentially interacts with PIK3C3/PIK3R4. Suppression of NRBF2 phosphorylation by MTORC1 inhibition alters its binding preference from PIK3C3/PIK3R4 to ATG14/BECN1, leading to increased autophagic PtdIns3K complex assembly, as well as enhancement of ULK1 protein complex association. Consequently, NRBF2 in its unphosphorylated form promotes PtdIns3K lipid kinase activity and autophagy flux, whereas its phosphorylated form blocks them. This study reveals NRBF2 as a critical molecular switch of PtdIns3K and autophagy activation, and its on/off state is precisely controlled by MTORC1 through phosphorylation. Show less
To investigate whether high glucose (HG) induces mitochondrial dysfunction and promotes apoptosis in retinal Müller cells. Rat retinal Müller cells (rMC-1) grown in normal (N) or HG (30 mM glucose) me Show more
To investigate whether high glucose (HG) induces mitochondrial dysfunction and promotes apoptosis in retinal Müller cells. Rat retinal Müller cells (rMC-1) grown in normal (N) or HG (30 mM glucose) medium for 7 days were subjected to MitoTracker Red staining to identify the mitochondrial network. Digital images of mitochondria were captured in live cells under confocal microscopy and analyzed for mitochondrial morphology changes based on form factor (FF) and aspect ratio (AR) values. Mitochondrial metabolic function was assessed by measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using a bioenergetic analyzer. Cells undergoing apoptosis were identified by differential dye staining and TUNEL assay, and cytochrome c levels were assessed by Western blot analysis. Cells grown in HG exhibited significantly increased mitochondrial fragmentation compared to those grown in N medium (FF = 1.7 ± 0.1 vs. 2.3 ± 0.1; AR = 2.1 ± 0.1 vs. 2.5 ± 0.2; P < 0.01). OCR and ECAR were significantly reduced in cells grown in HG medium compared to those grown in N medium (steady state: 75% ± 20% of control, P < 0.02; 64% ± 22% of control, P < 0.02, respectively). These cells also exhibited a significant increase (∼2-fold) in the number of apoptotic cells compared to those grown in N medium (P < 0.01), with a concomitant increase in cytochrome c levels (247% ± 94% of control, P < 0.05). Findings indicate that HG-induced mitochondrial morphology changes and subsequent mitochondrial dysfunction may contribute to retinal Müller cell loss associated with diabetic retinopathy. Show less
Obesity is known to increase the risk of colorectal cancer. However, mechanisms underlying the pathogenesis of obesity-induced colorectal cancer are not completely understood. The purposes of this stu Show more
Obesity is known to increase the risk of colorectal cancer. However, mechanisms underlying the pathogenesis of obesity-induced colorectal cancer are not completely understood. The purposes of this study were to identify differentially expressed genes in the colon of mice with diet-induced obesity and to select candidate genes as early markers of obesity-associated abnormal cell growth in the colon. C57BL/6N mice were fed normal diet (11% fat energy) or high-fat diet (40% fat energy) and were euthanized at different time points. Genome-wide expression profiles of the colon were determined at 2, 4, 8, and 12 weeks. Cluster analysis was performed using expression data of genes showing log High-fat diet-fed mice showed significant increase in body weight and total visceral fat weight over 12 weeks. Time-course microarray analysis showed that 50, 47, 36, and 411 genes were differentially expressed at 2, 4, 8, and 12 weeks, respectively. Ten cluster profiles representing distinguishable patterns of genes differentially expressed over time were determined. Cluster 4, which consisted of genes showing the most significant alterations in expression in response to high-fat diet over 12 weeks, included Our data indicate that Show less
Aditya Dandekar, Yining Qiu, Hyunbae Kim+10 more · 2016 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
Bacterial endotoxin can induce inflammatory and metabolic changes in the host. In this study, we revealed a molecular mechanism by which a stress-inducible, liver-enriched transcription factor, cAMP-r Show more
Bacterial endotoxin can induce inflammatory and metabolic changes in the host. In this study, we revealed a molecular mechanism by which a stress-inducible, liver-enriched transcription factor, cAMP-responsive element-binding protein hepatic-specific (CREBH), modulates lipid profiles to protect the liver from injuries upon the bacterial endotoxin lipopolysaccharide (LPS). LPS challenge can activate CREBH in mouse liver tissues in a toll-like receptor (TLR)/MyD88-dependent manner. Upon LPS challenge, CREBH interacts with TNF receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase that functions as a key mediator of TLR signaling, and this interaction relies on MyD88. Further analysis demonstrated that TRAF6 mediates K63-linked ubiquitination of CREBH to facilitate CREBH cleavage and activation. CREBH directly activates expression of the gene encoding Apolipoprotein A4 (ApoA4) under LPS challenge, leading to modulation of high-density lipoprotein (HDL) in animals. CREBH deficiency led to reduced production of circulating HDL and increased liver damage upon high-dose LPS challenge. Therefore, TLR/MyD88-dependent, TRAF6-facilitated CREBH activation represents a mammalian hepatic defense response to bacterial endotoxin by modulating HDL. Show less
Functional defects of the ApoA5 protein have been identified as risk factors for hypertriglyceridemia, vascular diseases and susceptibility to metabolic syndrome (MetS). These associations are neither Show more
Functional defects of the ApoA5 protein have been identified as risk factors for hypertriglyceridemia, vascular diseases and susceptibility to metabolic syndrome (MetS). These associations are neither strong nor consistent in all populations studied. In this study, we investigated the association between the ApoA5 -1131T>C and -12,238T>C polymorphic loci in Korean patients with MetS. A total of 1074 subjects, including 415 patients with MetS and 659 healthy control subjects, were enrolled to investigate the affect of ApoA5 polymorphisms on risk of MetS. Genotyping of the ApoA5 polymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism techniques. The CC genotype and the dominant (TT vs. TC+CC) and recessive (TT+TC vs. CC) models of the -1131T>C polymorphism were associated with increased MetS susceptibility (p < 0.001, p = 0.018, and p = 0.002, respectively). The association was male-specific when stratified by gender. With regard to the -12,238T>C polymorphism, the TC and CC genotypes and the dominant (TT vs. TC+CC) and recessive (TT+TC vs. CC) models were frequently found in the patient group, compared with the control group (p = 0.001, p < 0.001, p < 0.001, and p = 0.031, respectively). The T-C, C-T, and C-C haplotypes of the ApoA5 -1131T>C and -12,238T>C polymorphisms were associated with an increased risk for MetS (p < 0.001, p = 0.001, and p < 0.001, respectively). The variant of the ApoA5 -1131T>C polymorphism was also associated with increased triglyceride (TG) levels. Dominant models of ApoA5 -1131T>C and -12,238T>C polymorphisms were associated with the risk components of MetS by the stratification analysis. The -1131C and -12,238C variants and the C-containing haplotypes of ApoA5 -1131T>C and -12,238T>C polymorphisms were associated with higher risk for MetS in the Korean population. The -1131C variant was also associated with the increased level of TG. Show less
Both the Wnt/β-catenin and Ras pathways are aberrantly activated in most human colorectal cancers (CRCs) and interact cooperatively in tumor promotion. Inhibition of these signaling may therefore be a Show more
Both the Wnt/β-catenin and Ras pathways are aberrantly activated in most human colorectal cancers (CRCs) and interact cooperatively in tumor promotion. Inhibition of these signaling may therefore be an ideal strategy for treating CRC. We identified KY1220, a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway, and synthesized its derivative KYA1797K. KYA1797K bound directly to the regulators of G-protein signaling domain of axin, initiating β-catenin and Ras degradation through enhancement of the β-catenin destruction complex activating GSK3β. KYA1797K effectively suppressed the growth of CRCs harboring APC and KRAS mutations, as shown by various in vitro studies and by in vivo studies using xenograft and transgenic mouse models of tumors induced by APC and KRAS mutations. Destabilization of both β-catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/β-catenin and Ras pathways. Show less
Wnt/β-catenin signaling has a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC). The present study aimed to determine whether genetic variation in the Wnt/β-catenin signaling pathway Show more
Wnt/β-catenin signaling has a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC). The present study aimed to determine whether genetic variation in the Wnt/β-catenin signaling pathway is associated with the development and/or progression of HCC and the survival of patients with hepatitis B virus (HBV)-associated HCC. We assessed seven single nucleotide polymorphisms (SNPs) of the AXIN1, AXIN2, CTNNB1, and WNT2 genes in 245 patients with HBV-associated HCC and 483 chronic HBV carriers without HCC. We analyzed the association of each SNP with HCC development or progression and overall survival. The CTNNB1 rs3864004 A allele was associated with a decreased risk of HCC development (P=0.049). Haplotype analysis revealed a significantly higher frequency of CTNNB1 G-A/G-A haplotype at rs3864004 and rs4135385 positions in patients with HCC than in chronic HBV carriers without HCC (P=0.042). The AXIN1 rs1805105 T>C SNP was associated with small tumor size and early tumor stage and the WNT2 rs39315 G allele was associated with advanced tumor stage in HCC. In Kaplan-Meier analysis, carriers of the AXIN1 rs214252 C allele showed longer survival than those with the TT genotype (P=0.020). In multivariate Cox regression analysis, absence of CTNNB1 haplotype A-A at rs3864004 and rs4135385 positions and advanced tumor stage were independent poor predictors of patient survival in patients with HCC. These findings suggest that the genetic polymorphisms in CTNNB1 gene might affect tumor development and survival in patients with HBV-associated HCC. Show less
Bone mineral density (BMD) is a measure of osteoporosis and is useful in evaluating the risk of fracture. In a genome-wide association study of BMD among 20,100 Icelanders, with follow-up in 10,091 su Show more
Bone mineral density (BMD) is a measure of osteoporosis and is useful in evaluating the risk of fracture. In a genome-wide association study of BMD among 20,100 Icelanders, with follow-up in 10,091 subjects of European and East-Asian descent, we found a new BMD locus that harbours the PTCH1 gene, represented by rs28377268 (freq. 11.4-22.6%) that associates with reduced spine BMD (P=1.0 × 10(-11), β=-0.09). We also identified a new spine BMD signal in RSPO3, rs577721086 (freq. 6.8%), that associates with increased spine BMD (P=6.6 × 10(-10), β=0.14). Importantly, both variants associate with osteoporotic fractures and affect expression of the PTCH1 and RSPO3 genes that is in line with their influence on BMD and known biological function of these genes. Additional new BMD signals were also found at the AXIN1 and SOST loci and a new lead SNP at the EN1 locus. Show less
Batten disease (BD; also known as juvenile neuronal ceroid lipofuscinosis) is a genetic disorder inherited as an autosomal recessive trait and is characterized by blindness, seizures, cognitive declin Show more
Batten disease (BD; also known as juvenile neuronal ceroid lipofuscinosis) is a genetic disorder inherited as an autosomal recessive trait and is characterized by blindness, seizures, cognitive decline, and early death resulting from the inherited mutation of the CLN3 gene. Mitochondrial oxidative stress, endoplasmic reticulum (ER) stress, disrupted autophagy, and enhanced apoptosis have been suggested to play a role in BD pathogenesis. Fibrates, a class of lipid-lowering drugs that induce peroxisome proliferator-activated receptor-α (PPAR-α) activation, are the most commonly used PPAR agonists. Assuming that fibrates have a neuroprotective effect, we studied the effects of fibrates, fenofibrate, bezafibrate, and gemfibrozil on apoptosis, depolarization of mitochondrial membrane, and defective autophagy in BD lymphoblast cells. The viability of fibrate-treated BD lymphoblast cells increased to levels of normal lymphoblast cells. In addition, treatment with fibrates inhibited depolarization of mitochondrial membrane potential in BD lymphoblast cells. Defective autophagy in BD lymphoblast cells was normalized when treated with fibrates as indicated by increased acridine orange staining. The recovery of autophagy in BD lymphoblast cells is most likely attributed to the upregulation of autophagy proteins, lysosomal-associated membrane protein 1 (LAMP1), and LC3 I/II, after treatment with fibrates. This study therefore suggests that fibrates may have a therapeutic potential against BD. Show less
Mouse CA1 pyramidal neurons express apamin-sensitive SK2-containing channels in the post-synaptic membrane, positioned close to NMDA-type (N-methyl-D-aspartate) glutamate receptors. Activated by synap Show more
Mouse CA1 pyramidal neurons express apamin-sensitive SK2-containing channels in the post-synaptic membrane, positioned close to NMDA-type (N-methyl-D-aspartate) glutamate receptors. Activated by synaptically evoked NMDAR-dependent Ca(2+) influx, the synaptic SK2-containing channels modulate excitatory post-synaptic responses and the induction of synaptic plasticity. In addition, their activity- and protein kinase A-dependent trafficking contributes to expression of long-term potentiation (LTP). We have identified a novel synaptic scaffold, MPP2 (membrane palmitoylated protein 2; p55), a member of the membrane-associated guanylate kinase (MAGUK) family that interacts with SK2-containing channels. MPP2 and SK2 co-immunopurified from mouse brain, and co-immunoprecipitated when they were co-expressed in HEK293 cells. MPP2 is highly expressed in the post-synaptic density of dendritic spines on CA1 pyramidal neurons. Knocking down MPP2 expression selectively abolished the SK2-containing channel contribution to synaptic responses and decreased LTP. Thus, MPP2 is a novel synaptic scaffold that is required for proper synaptic localization and function of SK2-containing channels. Show less
While chromosome 1 is the largest chromosome in the human genome, less than two dozen cases of interstitial microdeletions in the short arm have been documented. More than half of the 1p microdeletion Show more
While chromosome 1 is the largest chromosome in the human genome, less than two dozen cases of interstitial microdeletions in the short arm have been documented. More than half of the 1p microdeletion cases were reported in the pre-microarray era and as a result, the proximal and distal boundaries containing the exact number of genes involved in the microdeletions have not been clearly defined. We revisited a previous case of a 10-year old female patient with a 1p32.1p32.3 microdeletion displaying syndromic intellectual disability. We performed microarray analysis as well as qPCR to define the proximal and distal deletion breakpoints and revised the karyotype from 1p32.1p32.3 to 1p31.3p32.2. The deleted chromosomal region contains at least 35 genes including NFIA. Comparative deletion mapping shows that this region can be dissected into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced transcript levels in RT-qPCR. Importantly, one patient with an intragenic microdeletion within NFIA and an additional patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly. We propose NFIA is responsible for intellectual disability coupled with macrocephaly, and microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to syndromic intellectual disability. Show less
The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extende Show more
The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extended survival in patients with melanoma who bear tumors that express mutations encoding BRAF proteins mutant at Val600, but a vast majority of these patients develop drug resistance. Here we show that loss of stromal antigen 2 (STAG2) or STAG3, which encode subunits of the cohesin complex, in melanoma cells results in resistance to BRAFi. We identified loss-of-function mutations in STAG2, as well as decreased expression of STAG2 or STAG3 proteins in several tumor samples from patients with acquired resistance to BRAFi and in BRAFi-resistant melanoma cell lines. Knockdown of STAG2 or STAG3 expression decreased sensitivity of BRAF(Val600Glu)-mutant melanoma cells and xenograft tumors to BRAFi. Loss of STAG2 inhibited CCCTC-binding-factor-mediated expression of dual specificity phosphatase 6 (DUSP6), leading to reactivation of mitogen-activated protein kinase (MAPK) signaling (via the MAPKs ERK1 and ERK2; hereafter referred to as ERK). Our studies unveil a previously unknown genetic mechanism of BRAFi resistance and provide new insights into the tumor suppressor function of STAG2 and STAG3. Show less
Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition o Show more
Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult liver metastases in a preclinical model. Liver metastases harvested from two patients with PDAC (Tumors 608, 366) were implanted orthotopically in mice. Tumor cell lines were derived and transduced with lentiviruses encoding luciferase and injected into spleens of mice generating microscopic liver metastases. Growth kinetics of liver metastases were measured with bioluminescent imaging and time-to-progression (TTP), progression-free survival (PFS), and overall survival (OS) were determined. Trametinib (0.3 mg/kg BID) significantly prolonged OS versus control (Tumor 608: 114 vs. 43 days, p < 0.001; Tumor 366: not reached vs. 167 days, p = 0.0488). In vivo target validation demonstrated trametinib significantly reduced phosphorylated-ERK and expression of the ERK-responsive gene DUSP6. In a randomized, preclinical trial, mice were randomized to: (1) control, (2) adjuvant Gem (100 mg/kg IP, Q3 days) × 7 days followed by surveillance, or (3) adjuvant Gem followed by trametinib. Sequential Gem-trametinib significantly decreased metastatic cell outgrowth and increased TTP and PFS. Treatment of mice bearing micrometastases with trametinib significantly delayed tumor outgrowth by effectively inhibiting KRAS-MEK-ERK signaling. In a randomized, preclinical, murine trial adjuvant sequential Gem followed by trametinib inhibited occult metastatic cell outgrowth in the liver and increased PFS versus adjuvant Gem alone. An adjuvant trial of sequential Gem-trametinib is being planned in patients with resected PDAC. Show less
Fads3 is the third member of the fatty acid desaturase gene cluster; with at least eight evolutionarily conserved alternative transcripts (AT), having no clearly established function as are known for Show more
Fads3 is the third member of the fatty acid desaturase gene cluster; with at least eight evolutionarily conserved alternative transcripts (AT), having no clearly established function as are known for FADS2 and FADS1. Here we present identification of a novel Fads3 transcript in mice (Fads3AT9), characterize Fads3AT9 expression in mouse tissues and evaluate correlations with metabolite profiles. Total RNA obtained from mouse tissues is reverse-transcribed into cDNA and used as template for PCR reactions. Tissue fatty acids were extracted and quantified by gas chromatography. Sequencing analysis revealed complete absence of exon 2 resulting in an open reading frame of 1239 bp, encoding a putative protein of 412 aa with loss of 37 aa compared to classical Fads3 (Fads3CS). FADS3AT9 retains all the conserved regions characteristic of front end desaturase (cytochrome b5 domain and three histidine repeats). Both Fads3CS and Fads3AT9 are ubiquitously expressed in 11 mouse tissues. Fads3AT9 abundance was greater than Fads3CS in pancreas, liver, spleen, brown adipose tissue and thymus. Fads3CS expression is low in pancreas while Fads3AT9 is over ten-fold greater abundance. The eicosanoid precursor fatty acid 20:4n - 6, the immediate desaturation product of the Fads1 coded Δ5-desaturase, was highest in pancreas where Fads3CS is low. Changes in expression patterns and fatty acid profiles suggest that Fads3AT9 may play a role in the regulation and/or biosynthesis of long chain polyunsaturated fatty acids from precursors. Show less
Coronary artery disease (CAD) is the leading cause of mortality and morbidity, driven by both genetic and environmental risk factors. Meta-analyses of genome-wide association studies have identified > Show more
Coronary artery disease (CAD) is the leading cause of mortality and morbidity, driven by both genetic and environmental risk factors. Meta-analyses of genome-wide association studies have identified >150 loci associated with CAD and myocardial infarction susceptibility in humans. A majority of these variants reside in non-coding regions and are co-inherited with hundreds of candidate regulatory variants, presenting a challenge to elucidate their functions. Herein, we use integrative genomic, epigenomic and transcriptomic profiling of perturbed human coronary artery smooth muscle cells and tissues to begin to identify causal regulatory variation and mechanisms responsible for CAD associations. Using these genome-wide maps, we prioritize 64 candidate variants and perform allele-specific binding and expression analyses at seven top candidate loci: 9p21.3, SMAD3, PDGFD, IL6R, BMP1, CCDC97/TGFB1 and LMOD1. We validate our findings in expression quantitative trait loci cohorts, which together reveal new links between CAD associations and regulatory function in the appropriate disease context. Show less
Minhan Ka, Woo-Yang Kim · 2016 · Molecular neurobiology · Springer · added 2026-04-24
Dendritic arborization and axon outgrowth are critical steps in the establishment of neural connectivity in the developing brain. Changes in the connectivity underlie cognitive dysfunction in neurodev Show more
Dendritic arborization and axon outgrowth are critical steps in the establishment of neural connectivity in the developing brain. Changes in the connectivity underlie cognitive dysfunction in neurodevelopmental disorders. However, molecules and associated mechanisms that play important roles in dendritic and axon outgrowth in the brain are only partially understood. Here, we show that microtubule-actin crosslinking factor 1 (MACF1) regulates dendritic arborization and axon outgrowth of developing pyramidal neurons by arranging cytoskeleton components and mediating GSK-3 signaling. MACF1 deletion using conditional mutant mice and in utero gene transfer in the developing brain markedly decreased dendritic branching of cortical and hippocampal pyramidal neurons. MACF1-deficient neurons showed reduced density and aberrant morphology of dendritic spines. Also, loss of MACF1 impaired the elongation of callosal axons in the brain. Actin and microtubule arrangement appeared abnormal in MACF1-deficient neurites. Finally, we found that GSK-3 is associated with MACF1-controlled dendritic differentiation. Our findings demonstrate a novel role for MACF1 in neurite differentiation that is critical to the creation of neuronal connectivity in the developing brain. Show less
Transforming growth factor-β1 (TGF-β1) promotes tumor metastasis by inducing an epithelial-to-mesenchymal transition (EMT) in cancer cells. In this study, we investigated the effects of BIX02189 and X Show more
Transforming growth factor-β1 (TGF-β1) promotes tumor metastasis by inducing an epithelial-to-mesenchymal transition (EMT) in cancer cells. In this study, we investigated the effects of BIX02189 and XMD8-92, pharmacologic inhibitors of the MEK5 [mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK)5] signaling pathway, on the EMT and migration of cancer cells induced by TGF-β1. In human A549 lung cancer cells, TGF-β1-induced EMT, cell motility, and expression of matrix metalloproteinase-2 were completely inhibited by BIX02189, but not by XMD8-92 or small interference RNAs specific to MEK5 and ERK5. Interestingly, BIX02189 strongly blocked the activation of TGF-β1 signaling components, and this inhibitory effect was not reproduced by MEK5 inhibition. Molecular docking simulation and kinase assays revealed that BIX02189 binds directly to the ATP-binding site of the TGF-β receptor type I (TβRI) and suppresses its kinase activity. Finally, the anti-metastatic effect of BIX02189 was validated in a TβRI-derived A549 xenograft mouse model. Collectively, these findings newly characterize BIX02189 as a potent inhibitor of TβRI that can block the tumor metastatic activity of TGF-β1. Show less